A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

ICER Proves Its Lack of Business Acumen, Again

/
A recent Institute for Clinical and Economic Review (ICER) “Report on Unsupported Price Increases,” concluded that: “Among the top drugs with price increases in 2019…ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known.”  The impression left by the report is that drug companies arbitrarily raise prices without good reason.  As with so many ICER products, the study is misleading and demonstrates a profound lack of business acumen.

Report: Rare Disease Patients Hurt by “One-Size-Fits-All” ICER Framework

/
This op-ed appeared in ICERWatch on June 26, 2019. The Institute…

Putting a Price on Life: The Coming Fight Over Government Rationing of Medical Care

/
This article appeared on The Mackinac Center for Public Policy…

Issue Brief: Problems With The Institute of Clinical and Economic Review (ICER) and the QALY Methodology

/
This article by Chris Rochester appeared in The MacIver Institute…

Commentary: Proposed Drug Price Caps Would Stall Advances in Health Care

/
This op-ed by William Smith and Adam Crepeau appeared in the…

HHS Secretary Alex Azar doesn’t want drug access to become an equation

/
This op-ed by William Smith appeared in the Washington Examiner…

The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews

/
This op-ed by William Smith appeared in STAT News on February…

Baker’s Orwellian drug pricing policy

/
This op-ed by William Smith appeared in Commonwealth Magazine…